Economic analysis in clinical trials: Practical considerations

Drug Information Journal

Volumn 33, Issue 4, 1999, Pages 1053-1060

  Baker, Andrew M ^a   Goldberg Arnold, Renée J ^b,c,d   Kaniecki, Diana J ^b,e  

^a PFIZER INC   (United States)

^b Pharmacon International Inc   (United States)

^c Arnold and Marie Schwartz College of Pharmacy   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

Economic; Resource; Trials; Utilization; Valuation

Indexed keywords

DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG RESEARCH; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; SELF REPORT;

EID: 0344614522     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300409     Document Type: Article

References (21)

1. Larson LN. Cost determination and analysis. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics. Cincinnati, Ohio: Harvey Whitney Books Company; 1991:35-49.
2. Eisenberg JM, Schulman KA, Glick H, Koffer H. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom B, ed. Pharmacoepidemiology. Second edition. Chichester, England: John Wiley and Sons Ltd; 1994.
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994;330:956-961.
4. Drummond D. Economic analysis alongside clinical trials: problems and potential. J Rheumatol. 1995; 22:1403-1407.
5. Luce BR, Elixhauser A. Issues in study design. In: Standards for the Socioeconomic Evaluation of Healthcare Products and Services. Berlin: Springer-Verlag; 1990:83-93.
6. Leidl RM. Some factors to consider when using the results of economic evaluation studies at the population level. Int J Tech Assess Health Care. 1994;10:467-478.
7. Rittenhouse BE. Exorcising protocol-induced spirits: making the clinical trial relevant for economics. Med Decis Making. 1997;17:331-339.
8. Bentkover JD, Baker AM, Kaplan H. Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. PharmacoEconomics. 1994;5(4):335-342.
9. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J. 1994;150:1083-1090.
10. Drummond MF. Methodological principles for economic evaluation of pharmaceuticals. Br J Med Econ. 1993;6B:1-18.
11. Weinstein MC, Fineberg HV. Structuring clinical decisions under uncertainty. In: Clinical Decision Analysis. Philadelphia, PA: WB Saunders Co.; 1980:12-36.
12. Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting methodological issues. Int J Tech Assess Health Care. 1991;7:561-573.
13. Schulman KA, Buxton M, Glick H, et al. Results of the economic evaluation of the FIRST study. Intl J Tech Assess Hlth Care. 1996;12:698-713.
14. Finkler SA. The distinction between cost and charges. Ann Int Med. 1982;96:102-109.
15. Arnold RJG, Pettit KG, DiCesare J, Fastenau J, Kaniecki DJ. Prospective economic evaluation in a Phase IIIb renal transplant clinical trial. Value in Health. 1998;1:36 (abstract).
16. Copley-Merriman C, Lair TJ. Valuation of medical resource units collected in health economic studies. Clin Ther. 1994;16:533-568.
17. Kirschner CG et al., eds. The Physician's Current Procedural Terminology Codes. Chicago, IL: American Medical Association; 1994.
18. Health Care Financing Administration Common Procedure Coding System. Washington, DC: U.S. Department of Health and Human Services, Health Care Financing Administration; 1995.
19. International Classification of Diseases, Ninth Revision: Clinical Modification. 4th ed. Code Book. Chicago, IL: American Medical Association; 1994.
20. Health Care Financing Administration, US Dept of Health and Human Services. Medicare program: prospective payments for Medicare inpatient hospital services. Federal Register. September 1, 1983;48: 39752-39890.
21. Rittenhouse B. How to extract economic information from clinical trial data. Presented at the Drug Information Workshop "Health Economics: The Impact of Economic Evaluation on New Drug Development and Marketing," Lisbon, Portugal: 1993.